Relugolix Pregnancy Registry: An Observational Study of the Safety of Relugolix-Containing Therapy Exposure in Pregnant Women and Their Offspring

Recruiting

RelugolixRelugolix Pregnancy Registry: An Observational Study of the Safety of Relugolix-Containing Therapy Exposure in Pregnant Women and Their Offspring

Sponsor:

Sumitomo Pharma Switzerland GmbH

Code:

NCT05739123

Conditions

Pregnancy Related

Pregnancy Complications

Pregnancy, High Risk

Eligibility Criteria

Sex: Female

Age: 0 - 70+

Healthy Volunteers: Not accepted

Interventions

Relugolix-Containing Product

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-08-19. This information was provided to ClinicalTrials.gov by Sumitomo Pharma Switzerland GmbH on 2024-05-16.